Merck’s integrase inhibitor Isentress (raltegravir) continues to perform well, compared with Sustiva (efavirenz), after four years in people living with HIV starting therapy for the first time in the company’s STARTMRK clinical trial. For those who do develop HIV drug resistance to Isentress, the experimental integrase inhibitor dolutegravir (S/GSK-572) showed promise as a second-line treatment option in ViiV Healthcare’s VIKING study. Both sets of study conclusions were reported Thursday, October 13, at the 13th European AIDS Conference in Belgrade, Serbia.
↧